Cargando…

Exploring Risk Factors for Follicular Lymphoma

Follicular lymphoma (FL) is an indolent malignancy of germinal center B cells with varied incidence across racial groups and geographic regions. Improvements in the classification of non-Hodgkin lymphoma subtypes provide an opportunity to explore associations between environmental exposures and FL i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambinder, Alexander J., Shenoy, Pareen J., Malik, Neha, Maggioncalda, Alison, Nastoupil, Loretta J., Flowers, Christopher R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458409/ https://www.ncbi.nlm.nih.gov/pubmed/23028387 http://dx.doi.org/10.1155/2012/626035

Ejemplares similares

Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma
por: Maggioncalda, Alison, et al.
Publicado: (2011)

Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States
por: Shenoy, Pareen, et al.
Publicado: (2011)

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States
por: Nastoupil, Loretta J, et al.
Publicado: (2014)

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis
por: Luan, Danny, et al.
Publicado: (2022)

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
por: Munoz, Javier, et al.
Publicado: (2021)

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale, Melody B, et al.
Publicado: (2017)

Development of the Lymphoma Enterprise Architecture Database: A caBIG(tm) Silver level compliant System
por: Huang, Taoying, et al.
Publicado: (2009)

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
por: AbouYabis, Abeer N., et al.
Publicado: (2011)

Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews
por: Monga, Neerav, et al.
Publicado: (2020)

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
por: Matasar, Matthew J., et al.
Publicado: (2019)

Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population
por: Moore, Susan G, et al.
Publicado: (2009)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Prescription Opioid Usage and Abuse Relationships: An Evaluation of State Prescription Drug Monitoring Program Efficacy
por: Reisman, Richard M., et al.
Publicado: (2009)

A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale
por: Gordon, Max J., et al.
Publicado: (2023)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
por: Han, Guangchun, et al.
Publicado: (2022)

The pathobiology of follicular lymphoma
por: Carreras, Joaquim
Publicado: (2023)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
por: Silvestre, Antonio Salar, et al.
Publicado: (2023)

Targeted Treatment of Follicular Lymphoma
por: Nath, Karthik, et al.
Publicado: (2021)

Follicular lymphoma: updates for pathologists
por: Khanlari, Mahsa, et al.
Publicado: (2022)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Flinn, Ian W., et al.
Publicado: (2023)

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

T follicular helper cells: a potential therapeutic target in follicular lymphoma
por: Ochando, Jordi, et al.
Publicado: (2017)

Novel Drugs in Follicular Lymphoma
por: Anastasia, Antonella, et al.
Publicado: (2016)

Treatment of high-risk follicular lymphoma
por: Jurczak, Wojciech
Publicado: (2019)

Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2021)

Follicular lymphoma - treatment and prognostic factors
por: Luminari, Stefano, et al.
Publicado: (2012)

Follicular Lymphoma
por: Yavaşoğlu, İrfan
Publicado: (2015)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

New targets for the treatment of follicular lymphoma
por: Tageja, Nishant, et al.
Publicado: (2009)

Follicular lymphoma and marginal zone lymphoma: how many diseases?
por: Laurent, Camille, et al.
Publicado: (2022)

FDG-PET in Follicular Lymphoma Management
por: Bodet-Milin, C., et al.
Publicado: (2012)

Follicular Lymphoma: The Management of Elderly Patient
por: Castellino, Alessia, et al.
Publicado: (2017)

Infections and Follicular Lymphoma: is there a Link?
por: Zallio, Francesco, et al.
Publicado: (2017)

A rare face of follicular lymphoma: reverse variant of follicular lymphoma
por: Maskey, Ninu, et al.
Publicado: (2020)

Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models
por: Li, Yanan, et al.
Publicado: (2022)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v7odaoprms0v873otts9cpbpmi